SEL120-34A is a novel CDK8 inhibitor active in AML cells with high levels of serine phosphorylation of STAT1 and STAT5 transactivation domains

Oncotarget

Volumn 8, Issue 20, 2017, Pages 33779-33795

  Rzymski, Tomasz ^a   Mikula, Michal ^b   Zylkiewicz, Eliza ^a   Dreas, Agnieszka ^a   Wiklik, Katarzyna ^a   Golas, Aniela ^a   Wójcik, Katarzyna ^a   Masiejczyk, Magdalena ^a   Wróbel, Anna ^a   Dolata, Izabela ^a   Kitlinska, Agata ^a   Statkiewicz, Malgorzata ^b   Kuklinska, Urszula ^b   Goryca, Krzysztof ^b   Sapala, Lukasz ^a   Grochowska, Aleksandra ^c   Cabaj, Aleksandra ^b,d   Szajewska Skuta, Malgorzata ^a   Gabor Worwa, Ewelina ^a   Kucwaj, Katarzyna ^a   Bialas, Arkadiusz ^a   Radzimierski, Adam ^a   Combik, Michal ^a   Woyciechowski, Jakub ^a   Mikulski, Maciej ^a   Windak, Renata ^a   Ostrowski, Jerzy ^b,c   Brzózka, Krzysztof ^a   more..

^a Selvita Sp   (Poland)

^b INSTITUTE OF ONCOLOGY   (Poland)

^c MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

^d NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY   (Poland)

Author keywords

AML; CDK8 mediator; Kinase inhibitor; Leukemia stem cells; STAT5

Indexed keywords

BENZIMIDAZOLE DERIVATIVE; CYCLIN DEPENDENT KINASE 8; DOCETAXEL; EARLY GROWTH RESPONSE FACTOR 1; INTERFERON REGULATORY FACTOR 9; MESSENGER RNA; NUCLEOPORIN 98; PROTEIN FOS; SEL 120 34A; SERINE; STAT1 PROTEIN; STAT5 PROTEIN; TRANSCRIPTION FACTOR HOXA9; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PROTEIN BINDING; PROTEIN KINASE INHIBITOR;

ACUTE MYELOID LEUKEMIA; ACUTE MYELOID LEUKEMIA CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BINDING; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG STRUCTURE; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; GENE REPRESSION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; TRANSCRIPTOMICS; TUMOR XENOGRAFT; ANIMAL; CHEMISTRY; CONFORMATION; DISEASE MODEL; DRUG EFFECT; DRUG SCREENING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MOLECULAR MODEL; PHOSPHORYLATION; PROTEIN DOMAIN; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE 8; DISEASE MODELS, ANIMAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN KINASE INHIBITORS; STAT1 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85019225436     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.16810     Document Type: Article

References (57)

1. Knuesel MT, Meyer KD, Bernecky C, Taatjes DJ. The human CDK8 subcomplex is a molecular switch that controls Mediator coactivator function. Genes Dev. 2009; 23: 439-51. doi: 10.1101/gad.1767009
2. Rzymski T, Mikula M, Wiklik K, Brzózka K. CDK8 kinase-An emerging target in targeted cancer therapy. Biochim Biophys Acta. 2015; 1854: 1617-29. doi: 10.1016/j. bbapap.2015.05.011
3. Cee VJ, Chen DY-K, Lee MR, Nicolaou KC. Cortistatin A is a High-Affinity Ligand of Protein Kinases ROCK, CDK8, and CDK11. Angew Chemie Int Ed. 2009; 48: 8952-7. doi: 10.1002/anie.200904778
4. Pelish HE, Liau BB, Nitulescu II, Tangpeerachaikul A, Poss ZC, Da Silva DH, Caruso BT, Arefolov A, Fadeyi O, Christie AL, Du K, Banka D, Schneider E V, et al. Mediator kinase inhibition further activates superenhancer-associated genes in AML. Nature. 2015; 526:273-6. doi: 10.1038/nature14904
5. Koehler MFT, Bergeron P, Blackwood EM, Bowman K, Clark KR, Firestein R, Kiefer JR, Maslos K, McCleland ML, Orren L, Salphati L, Schmidt S, Schneider E V, et al. Potent, Specific CDK8 Kinase Inhibitors Lack CDK8-dependent Antiproliferative Activity in HCT-116 Colon Cancer Cell Line. ACS Med Chem Lett. 2016; 7:223-8. doi: 10.1021/acsmedchemlett.5b00278
6. Poss ZC, Ebmeier CC, Odell AT, Tangpeerachaikul A, Lee T, Pelish HE, Shair MD, Dowell RD, Old WM, Taatjes DJ. Identification of Mediator Kinase Substrates in Human Cells using Cortistatin A and Quantitative Phosphoproteomics. Cell Rep. 2016; 1-15. doi: 10.1016/j. celrep.2016.03.030
7. Firestein R, Bass AJ, Kim SY, Dunn IF, Silver SJ, Guney I, Freed E, Ligon AH, Vena N, Ogino S, Chheda MG, Tamayo P, Finn S, et al. CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature. 2008; 455: 547-51. doi: 10.1038/nature07179
8. Donner AJ, Ebmeier CC, Taatjes DJ, Espinosa JM. CDK8 is a positive regulator of transcriptional elongation within the serum response network. Nat Struct Mol Biol. 2010; 17: 194-201. doi: 10.1038/nsmb.1752
9. Donner AJ, Szostek S, Hoover JM, Espinosa JM. CDK8 is a stimulus-specific positive coregulator of p53 target genes. Mol Cell. 2007; 27: 121-33. doi: 10.1016/j. molcel.2007.05.026
10. Porter DC, Farmaki E, Altilia S, Schools GP, West DK, Chen M, Chang BD, Puzyrev AT, Lim CU, Rokow-Kittell R, Friedhoff LT, Papavassiliou AG, Kalurupalle S, et al. Cyclindependent kinase 8 mediates chemotherapy-induced tumorpromoting paracrine activities. Proc Natl Acad Sci U S A. 2012; 109: 1-6. doi: 10.1073/pnas.1206906109
11. Fryer CJ, White JB, Jones KA. Mastermind recruits CycC:CDK8 to phosphorylate the Notch ICD and coordinate activation with turnover. Mol Cell. 2004; 16: 509-20. doi: 10.1016/j.molcel.2004.10.014
12. Galbraith MDD, Allen MAA, Bensard CLL, Wang X, Schwinn MKK, Qin B, Long HWW, Daniels DLL, Hahn WCC, Dowell RDD, Espinosa JMM. HIF1A Employs CDK8-Mediator to Stimulate RNAPII Elongation in Response to Hypoxia. Cell. 2013; 153: 1327-39. doi: 10.1016/j.cell.2013.04.048
13. Mallinger A, Schiemann K, Rink C, Stieber F, Calderini M, Crumpler S, Stubbs M, Adeniji-Popoola O, Poeschke O, Busch M, Czodrowski P, Musil D, Schwarz D, et al. Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19. J Med Chem. 2016; 1-123. doi: 10.1021/acs.jmedchem.5b01685
14. Dale T, Clarke PA, Esdar C, Waalboer D, Adeniji-Popoola O, Ortiz-Ruiz M-J, Mallinger A, Samant RS, Czodrowski P, Musil D, Schwarz D, Schneider K, Stubbs M, et al. A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease. Nat Chem Biol. 2015; 11: 973-80. doi: 10.1038/nchembio.1952
15. Galbraith MD, Donner AJ, Espinosa JM. CDK8: a positive regulator of transcription. Transcription. 2010; 1: 4-12. doi: 10.4161/trns.1.1.12373
16. Zhao J, Ramos R, Demma M. CDK8 regulates E2F1 transcriptional activity through S375 phosphorylation. Oncogene. 2013; 32: 3520-30. doi: 10.1038/onc.2012.364
17. Bancerek J, Poss ZC, Steinparzer I, Sedlyarov V, Pfaffenwimmer T, Mikulic I, Dölken L, Strobl B, Müller M, Taatjes DJ, Kovarik P. CDK8 kinase phosphorylates transcription factor STAT1 to selectively regulate the interferon response. Immunity. 2013; 38: 250-62. doi: 10.1016/j.immuni.2012.10.017
18. Akoulitchev S, Chuikov S, Reinberg D. TFIIH is negatively regulated by cdk8-containing mediator complexes. Nature. 2000; 407: 102-6. doi: 10.1038/35024111
19. Berman HM, Kleywegt GJ, Nakamura H, Markley JL. The Protein Data Bank archive as an open data resource. J Comput Aided Mol Des. 2014; 1009-14. doi: 10.1007/s10822-014-9770-y
20. Porter DC, Liang J, Kaza V, Chumanevich AA, Altilia S, Farmaki E, Chen M, Schools GP, Chatzistamou I, Pena MM, Friedhoff LT, Wentland MP, Broude E V., et al. Targeting the seed and the soil of cancers with selective small-molecule inhibitors of CDK8/19: Chemopotentiating, chemopreventive, anti-invasive and anti-metastatic activities. AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. 2014
21. Mallinger A, Crumpler S, Pichowicz M, Waalboer D, Stubbs M, Adeniji-Popoola O, Wood B, Smith E, Thai C, Henley AT, Georgi K, Court W, Hobbs S, et al. Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen. J Med Chem. 2015; 58: 1717-35. doi: 10.1021/jm501436m
22. Schneider E V, Böttcher J, Huber R, Maskos K, Neumann L. Structure-kinetic relationship study of CDK8/CycC specific compounds. Proc Natl Acad Sci U S A. 2013; 110: 8081-6. doi: 10.1073/pnas.1305378110
23. Wen Z, Zhong Z, Darnell JE. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell. 1995; 82: 241-50
24. Chao SH, Price DH. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem. 2001; 276: 31793-9. doi: 10.1074/jbc.M102306200
25. Baumli S, Lolli G, Lowe ED, Troiani S, Rusconi L, Bullock AN, Debreczeni JE, Knapp S, Johnson LN. The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation. EMBO J. 2008; 27: 1907-18. doi: 10.1038/emboj.2008.121
26. Uozumi K, Otsuka M, Ohno N, Moriyama T, Suzuki S, Shimotakahara S, Matsumura I, Hanada S, Arima T. Establishment and characterization of a new human megakaryoblastic cell line (SET-2) that spontaneously matures to megakaryocytes and produces platelet-like particles. Leukemia. 2000; 14: 142-52. doi: 10.1038/sj.leu.2401608
27. Amit I, Citri A, Shay T, Lu Y, Katz M, Zhang F, Tarcic G, Siwak D, Lahad J, Jacob-Hirsch J, Amariglio N, Vaisman N, Segal E, et al. A module of negative feedback regulators defines growth factor signaling. Nat Genet. 2007; 39: 503-12 doi: 10.1038/ng1987
28. Klampfer L, Huang J, Corner G, Mariadason J, Arango D, Sasazuki T, Shirasawa S, Augenlicht L. Oncogenic Ki-ras inhibits the expression of interferon-responsive genes through inhibition of STAT1 and STAT2 expression. J Biol Chem. 2003; 278: 46278-87. doi: 10.1074/jbc. M304721200
29. Einav U, Tabach Y, Getz G, Yitzhaky A, Ozbek U, Amariglio N, Izraeli S, Rechavi G, Domany E. Gene expression analysis reveals a strong signature of an interferon-induced pathway in childhood lymphoblastic leukemia as well as in breast and ovarian cancer. Oncogene. 2005; 24: 6367-75. doi: 10.1038/sj.onc.1208797
30. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette M a, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102: 15545-50. doi: 10.1073/pnas.0506580102
31. Dorsam ST, Ferrell CM, Dorsam GP, Derynck MK, Vijapurkar U, Khodabakhsh D, Pau B, Bernstein H, Haqq CM, Largman C, Lawrence HJ. The transcriptome of the leukemogenic homeoprotein HOXA9 in human hematopoietic cells. Blood. 2004; 103: 1676-84. doi: 10.1182/blood-2003-07-2202
32. Kroon E, Krosl J, Thorsteinsdottir U, Baban S, Buchberg AM, Sauvageau G. Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. EMBO J. 1998; 17: 3714-25. doi: 10.1093/emboj/17.13.3714
33. Huang Y, Sitwala K, Bronstein J, Sanders D, Dandekar M, Collins C, Robertson G, MacDonald J, Cezard T, Bilenky M, Thiessen N, Zhao Y, Zeng T, et al. Identification and characterization of Hoxa9 binding sites in hematopoietic cells. Blood. 2012; 119: 388-98. doi: 10.1182/blood-2011-03-341081
34. Thorsteinsdottir U, Mamo A, Kroon E, Jerome L, Bijl J, Lawrence HJ, Humphries K, Sauvageau G. Overexpression of the myeloid leukemia-associated Hoxa9 gene in bone marrow cells induces stem cell expansion. Blood. 2002; 99: 121-9. doi: 10.1182/blood.V99.1.121
35. Clarke PA, Ortiz-Ruiz M-J, TePoele R, Adeniji-Popoola O, Box G, Court W, Czasch S, El Bawab S, Esdar C, Ewan K, Gowan S, De Haven Brandon A, Hewitt P, et al. Assessing the mechanism and therapeutic potential of modulators of the human Mediator complex-associated protein kinases. Elife. 2016; 5. doi: 10.7554/eLife.20722
36. Tam WF, Hähnel PS, Schüler A, Lee BH, Okabe R, Zhu N, Pante S V, Raffel G, Mercher T, Wernig G, Bockamp E, Sasca D, Kreft A, et al. STAT5 is crucial to maintain leukemic stem cells in acute myelogenous leukemias induced by MOZ-TIF2. Cancer Res. 2013; 73: 373-84. doi: 10.1158/0008-5472.CAN-12-0255
37. Bose P, Grant S. Mcl-1 as a therapeutic target in acute myelogenous leukemia (AML). Leuk Res Reports. 2013; 2: 12-4. doi: 10.1016/j.lrr.2012.11.006
38. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov G V, Sonkin D, Reddy A, Liu M, Murray L, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483: 603-7. doi: 10.1038/nature11003
39. Yang YH, Xiao Y, Segal MR. Identifying differentially expressed genes from microarray experiments via statistic synthesis. Bioinformatics. 2005; 21: 1084-93. doi: 10.1093/bioinformatics/bti108
40. Watari K, Mayani H, Lee F, Dragowska W, Lansdorp PM, Schrader JW. Production of interleukin 1beta by human hematopoietic progenitor cells. J Clin Invest. 1996; 97: 1666-74. doi: 10.1172/JCI118593
41. Ivanova NB, Dimos JT, Schaniel C, Hackney J, Moore K, Lemischka IR. A stem cell molecular signature. Science. 2002; 298: 601-4. doi: 10.1126/science.1073823
42. Powell J a, Thomas D, Barry EF, Kok CH, McClure BJ, Tsykin A, To LB, Brown A, Lewis ID, Herbert K, Goodall GJ, Speed TP, Asou N, et al. Expression profiling of a hemopoietic cell survival transcriptome implicates osteopontin as a functional prognostic factor in AML. Blood. 2009; 114: 4859-70. doi: 10.1182/blood-2009-02-204818
43. Gerber JM, Smith BD, Ngwang B, Zhang H, Vala MS, Morsberger L, Galkin S, Collector MI, Perkins B, Levis MJ, Griffin C a, Sharkis SJ, Borowitz MJ, et al. A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia. Blood. 2012; 119: 3571-7. doi: 10.1182/blood-2011-06-364182
44. Quek L, Otto GW, Garnett C, Lhermitte L, Karamitros D, Stoilova B, Lau I-J, Doondeea J, Usukhbayar B, Kennedy A, Metzner M, Goardon N, Ivey A, et al. Genetically distinct leukemic stem cells in human CD34-acute myeloid leukemia are arrested at a hemopoietic precursor-like stage. J Exp Med. 2016; jem.20151775. doi: 10.1084/jem.20151775
45. Meissl K, Macho-Maschler S, Müller M, Strobl B. The good and the bad faces of STAT1 in solid tumours. Cytokine. 2015; doi: 10.1016/j.cyto.2015.11.011
46. Weichselbaum RR, Ishwaran H, Yoon T, Nuyten DS a, Baker SW, Khodarev N, Su AW, Shaikh AY, Roach P, Kreike B, Roizman B, Bergh J, Pawitan Y, et al. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci U S A. 2008; 105: 18490-5. doi: 10.1073/pnas.0809242105
47. Khodarev NN, Roizman B, Weichselbaum RR. Molecular pathways: interferon/stat1 pathway: role in the tumor resistance to genotoxic stress and aggressive growth. Clin Cancer Res. 2012; 18: 3015-21. doi: 10.1158/1078-0432. CCR-11-3225
48. Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, Bot BM, Morris JS, Simon IM, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015. doi: 10.1038/nm.3967
49. Putz EM, Gotthardt D, Hoermann G, Csiszar A, Wirth S, Berger A, Straka E, Rigler D, Wallner B, Jamieson AM, Pickl WF, Zebedin-Brandl EM, Müller M, et al. CDK8-Mediated STAT1-S727 Phosphorylation Restrains NK Cell Cytotoxicity and Tumor Surveillance. Cell Rep. 2013; 437-44 doi: 10.1016/j.celrep.2013.07.012
50. Schepers H, van Gosliga D, Wierenga ATJ, Eggen BJL, Schuringa JJ, Vellenga E. STAT5 is required for longterm maintenance of normal and leukemic human stem/progenitor cells. Blood. 2007; 110: 2880-8. doi: 10.1182/blood-2006-08-039073
51. Birkenkamp K, Geugien M, Lemmink H, Kruijer W, Vellenga E. Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts. Leukemia. 2001; 15: 1923-31. doi: 10.1038/sj.leu.2402317
52. Sternberg DW, Gilliland DG. The role of signal transducer and activator of transcription factors in leukemogenesis. J Clin Oncol. 2004; 22: 361-71. doi: 10.1200/JCO.2004.10.124
53. Friedbichler K, Kerenyi MA, Kovacic B, Li G, Hoelbl A, Yahiaoui S, Sexl V, Müllner EW, Fajmann S, Cerny-Reiterer S, Valent P, Beug H, Gouilleux F, et al. Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation. Blood. 2010; 116: 1548-58. doi: 10.1182/blood-2009-12-258913
54. Schneider E V, Böttcher J, Blaesse M, Neumann L, Huber R, Maskos K. The structure of CDK8/CycC implicates specificity in the CDK/cyclin family and reveals interaction with a deep pocket binder. J Mol Biol. 2011; 412: 251-66. doi: 10.1016/j.jmb.2011.07.020
55. Paziewska A, Dabrowska M, Goryca K, Antoniewicz A, Dobruch J, Mikula M, Jarosz D, Zapala L, Borowka A, Ostrowski J. DNA methylation status is more reliable than gene expression at detecting cancer in prostate biopsy. Br J Cancer. 2014; doi: 10.1038/bjc.2014.337
56. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 25: 25-9. doi: 10802651
57. Lin SM, Du P, Huber W, Kibbe WA. Model-based variancestabilizing transformation for Illumina microarray data. Nucleic Acids Res. 2008; 36: e11. doi: 10.1093/nar/gkm1075